title: Effects of KCNQ2 gene truncation on M-type Kv7 potassium currents.
abstract: The KCNQ2 gene product, Kv7.2, is a subunit of the M-channel, a low-threshold voltage-gated K(+) channel that regulates mammalian and human neuronal excitability. Spontaneous mutations one of the KCNQ2 genes cause disorders of neural excitability such as Benign Familial Neonatal Seizures. However there appear to be no reports in which both human KCNQ2 genes are mutated. We therefore asked what happens to M-channel function when both KCNQ2 genes are disrupted. We addressed this using sympathetic neurons isolated from mice in which the KCNQ2 gene was truncated at a position corresponding to the second transmembrane domain of the Kv7.2 protein. Since homozygote KCNQ2-/- mice die postnatally, experiments were largely restricted to neurons from late embryos. Quantitative PCR revealed an absence of KCNQ2 mRNA in ganglia from KCNQ2-/- embryos but 100-120% increase of KCNQ3 and KCNQ5 mRNAs; KCNQ2+/- ganglia showed ∼30% less KCNQ2 mRNA than wild-type (+/+) ganglia but 40-50% more KCNQ3 and KCNQ5 mRNA. Neurons from KCNQ2-/- embryos showed a complete absence of M-current, even after applying the Kv7 channel enhancer, retigabine. Neurons from heterozygote KCNQ2+/- embryos had ∼60% reduced M-current. In contrast, M-currents in neurons from adult KCNQ2+/- mice were no smaller than those in neurons from wild-type mice. Measurements of tetraethylammonium block did not indicate an increased expression of Kv7.5-containing subunits, implying a compensatory increase in Kv7.2 expression from the remaining KCNQ2 gene. We conclude that mouse embryonic M-channels have an absolute requirement for Kv7.2 subunits for functionality, that the reduced M-channel activity in heterozygote KCNQ2+/- mouse embryos results primarily from a gene-dosage effect, and that there is a compensatory increase in Kv7.2 expression in adult mice.
authors: Wolfson Centre for Age Related Disease, King's College London, London, United Kingdom.
authors: Jon
authors: J
authors: Robbins
authors: Gayle M
authors: GM
authors: Passmore
authors: Fe C
authors: FC
authors: Abogadie
authors: Joanne M
authors: JM
authors: Reilly
authors: David A
authors: DA
authors: Brown
mesh_terms: D000200:Action Potentials; D000818:Animals; D002219:Carbamates / Q000494:pharmacology; D002478:Cells, Cultured; D005260:Female; D015870:Gene Expression; D006801:Humans; D051658:KCNQ2 Potassium Channel / Q000235:genetics* / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009154:Mutation; D009419:Nerve Tissue Proteins / Q000235:genetics* / Q000378:metabolism; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D018408:Patch-Clamp Techniques; D010655:Phenylenediamines / Q000494:pharmacology; D026902:Potassium Channel Blockers / Q000494:pharmacology; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D017783:Superior Cervical Ganglion / Q000166:cytology; D019789:Tetraethylammonium / Q000494:pharmacology
chemical_list: D002219:Carbamates; D051658:KCNQ2 Potassium Channel; C114401:Kcnq2 protein, mouse; D009419:Nerve Tissue Proteins; D010655:Phenylenediamines; D026902:Potassium Channel Blockers; D012333:RNA, Messenger; C101866:ezogabine; D019789:Tetraethylammonium
references: Nat Rev Neurosci. 2000 Oct;1(1):21-30
references: 11252765
references: Annu Rev Physiol. 1997;59:483-504
references: 9074774
references: Physiology (Bethesda). 2011 Oct;26(5):365-76
references: 22013194
references: J Neurosci. 2004 Jun 2;24(22):5079-90
references: 15175377
references: J Physiol. 2000 Feb 1;522 Pt 3:349-55
references: 10713961
references: J Biol Chem. 2000 May 5;275(18):13343-8
references: 10788442
references: Front Physiol. 2012 Oct 16;3:397
references: 23087646
references: Brain. 2003 Dec;126(Pt 12):2726-37
references: 14534157
references: Br J Pharmacol. 2002 Dec;137(8):1173-86
references: 12466226
references: J Neurochem. 2000 Jul;75(1):28-33
references: 10854243
references: J Physiol. 2008 Apr 1;586(7):1791-801
references: 18238816
references: Nature. 1998 Dec 17;396(6712):687-90
references: 9872318
references: J Neurosci. 2001 Aug 1;21(15):5535-45
references: 11466425
references: Biophys J. 2008 Dec;95(11):5121-37
references: 18790849
references: J Neurosci. 2005 May 18;25(20):5051-60
references: 15901787
references: J Biol Chem. 2000 Jul 21;275(29):22395-400
references: 10787416
references: Pharmacol Ther. 2001 Apr;90(1):1-19
references: 11448722
references: Neuron. 2012 Dec 20;76(6):1133-46
references: 23259949
references: J Neurosci. 1999 Sep 15;19(18):7742-56
references: 10479678
references: J Neurosci. 2003 Jun 15;23(12):5012-9
references: 12832524
references: J Biol Chem. 2008 Nov 7;283(45):30668-76
references: 18786918
references: Br J Pharmacol. 2000 Feb;129(3):413-5
references: 10711337
references: Neuron. 2007 Mar 1;53(5):663-75
references: 17329207
references: Nature. 1980 Feb 14;283(5748):673-6
references: 6965523
references: J Neurosci. 2006 Mar 8;26(10):2599-613
references: 16525039
references: PLoS Genet. 2008 Dec;4(12):e1000317
references: 19112491
references: J Physiol. 2008 Jul 15;586(14):3405-23
references: 18483067
references: J Physiol. 2008 Apr 1;586(7):1803-10
references: 18218681
references: Br J Pharmacol. 2009 Apr;156(8):1185-95
references: 19298256
references: J Physiol. 2001 Jul 1;534(Pt 1):15-24
references: 11432988
references: Brain Res Mol Brain Res. 2005 Sep 13;139(1):52-62
references: 15963599
references: J Neurosci. 2003 Aug 6;23(18):7227-36
references: 12904483
references: Science. 1998 Dec 4;282(5395):1890-3
references: 9836639
references: J Neurosci. 2004 Oct 13;24(41):9146-52
references: 15483133
references: J Neurosci. 2001 Dec 15;21(24):9529-40
references: 11739564
references: J Biol Chem. 2000 Aug 4;275(31):24089-95
references: 10816588
references: Neurobiol Dis. 2006 Oct;24(1):194-201
references: 16916607
references: J Neurosci Methods. 1991 Mar;37(1):15-26
references: 2072734
references: J Neurosci. 2006 Feb 15;26(7):2053-9
references: 16481438
references: Nucleic Acids Res. 2003 Dec 15;31(24):e154
references: 14654707